Overview

Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy

Status:
Completed

Trial end date:
1999-11-01

Target enrollment:

Participant gender:

Summary

OBJECTIVES: I. Compare and evaluate the response to treatment with intravenous human immune globulin (IVIG) or placebo in previously untreated patients with chronic inflammatory demyelinating polyneuropathy.

Phase:

Phase 3

Details

Lead Sponsor:

National Center for Research Resources (NCRR)

Collaborator:

University of Vermont

Treatments:

Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin